Simple screening method for the diagnosis of nonB-nonC hepatocellular carcinoma

Abstract

Aim: The incidence of non-virus-related nonB-nonC hepatocellular carcinoma (NBNC-HCC) is on the rise. However, screening at-risk individuals using imaging methods is complicated by the large size of the at-risk patient pool. The aim of this study is to develop an effective simple screening method, using blood tests.

Methods: The diagnostic value of aspartate aminotransferase (AST), alpha-fetoprotein (AFP), and des-gamma-carboxy prothrombin (DCP) was analyzed using sera from 203 NBNB-HCC patients and 106 diabetes mellitus patients.

Results: Areas under receiver operating characteristic curves for AST, AFP, and DCP were 0.844, 0.901, and 0.914, respectively. The optimal cut-offs for diagnosing NBNC-HCC based on Youden indices were 30 IU/L, 3.6 ng/mL, and 25 mAU/mL, respectively. On selecting patients who were positive at least one parameter (AST, AFP, or DCP), the sensitivity was 97.5%. This high sensitivity was preserved (98.0%) even in cases of non-advanced HCC (≤ 3 cm, ≤ 3 nodules). Specificity was 72.6%.

Conclusion: This simple triple screen for AST, AFP, and DCP appears to have diagnostic value in NBNC-HCC and could be used to select candidates for further testing using imaging.

Keywords

Hepatocellular carcinoma / screening / diagnosis / alpha-fetoprotein / aspartate aminotransferase / desgamma-carboxy-prothrombin

References

[1] El-Serag HB.Epidemiology of viral hepatitis and hepatocellular carcinoma..Gastroenterology2012;142:1264-73 PMCID:PMC3338949

[2] Miyahara K,Yamamoto K.Image of the month. Hepatocellular carcinoma mimicking bile duct stone..Clin Gastroenterol Hepatol2010;8:e17

[3] Kudo M,Sakamoto M,Ichida T.Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan..Liver Cancer2016;5:190-7 PMCID:PMC4960353

[4] Hosaka T,Kobayashi M,Kawamura Y.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection..Hepatology2013;58:98-107

[5] Miyake Y,Yamamoto K.Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C..Int J Cancer2010;127:989-96

[6] Sung JJ,Wong VW,Chan HL.Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma..Aliment Pharmacol Ther2008;28:1067-77

[7] Tateishi R,Fujiwara N,Kiyosawa K.Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study..J Gastroenterol2015;50:350-60 PMCID:PMC4352653

[8] Archambeaud I,Nahon P,Fallot G.Risk factors for hepatocellular carcinoma in Caucasian patients with non-viral cirrhosis: the importance of prior obesity..Liver Int2015;35:1872-6

[9] Kokudo N,Akahane M,Izumi N.Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2013 update (3rd JSH-HCC Guidelines)..Hepatol Res2015;

[10] Forner A,Bruix J.Hepatocellular carcinoma..Lancet2018;391:1301-14

[11] International Diabetes Federation. IDF Diabetes Atlas - 8th edition. Available from: http://www.diabetesatlas.org. [Last accessed on 4 Dec 2018]

[12] Ishiguro S,Tanaka Y,Iwasaki M.Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan..Eur J Cancer Prev2009;18:26-32

[13] Wen CP,Yang YC,Tsao CK.Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases..J Natl Cancer Inst2012;104:1599-611 PMCID:PMC3692381

[14] Asahina Y,Nishimura T,Suzuki Y.α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C..Hepatology2013;58:1253-62

[15] Hiramatsu N,Takehara T.Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy..Hepatol Res2015;45:152-61

[16] Takeuchi Y,Osawa T,Takaguchi K.Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development..World J Hepatol2015;7:2220-8 PMCID:PMC4561777

[17] Ricco G,Cosma C,Oliveri F.Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers..Cancer Biomark2018;21:603-612

[18] Bruix J.Management of hepatocellular carcinoma: an update..Hepatology2011;53:1020-2 PMCID:PMC3084991

[19] Tateishi R,Matsuyama Y,Kondo Y.Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review..Hepatol Int2008;2:17-30 PMCID:PMC2716871